Meta-analyses, such as those by Kelly et al. (2021), underscore the utility of ctDNA for detecting actionable mutations (e.g., KIT and PDGFRA mutations in gastrointestinal stromal tumors) and assessing response to tyrosine kinase inhibitors [15]. The gene discussed is PDGFRA; the disease is gastrointestinal stromal tumor.